Fenghao Chen Ph.D.

Dr. Fenghao Chen is President and CEO of LINKMedicine.AI, a digital health innovator recognized by programs such as NVIDIA Inception and AWS Activate. At LINKMedicine.AI, he pioneers the integration of artificial intelligence and data technologies to advance the next generation of healthcare.  

Dr. Chen combines deep technical expertise with strategic business insight for the mission of making modern medicine more accessible. His work has been recognized through peer-reviewed publications, pioneering AI patents, and globally impactful public health projects. By embedding AI into healthcare systems, Dr. Chen and his team are setting new standards in patient navigation, medical referrals, and access to care - driving transformative, patient-centered outcomes.  

Previously, Dr. Chen held executive leadership roles at venture-backed proteomics startups, leading genomics research institutes, and nonprofit organizations. He is also a strong advocate for innovation and entrepreneurship within and beyond the Johns Hopkins community, mentoring teams in the NSF Innovation Corps (I-Corps™) program and advising science- and technology-driven ventures.  

Dr. Chen earned his Ph.D. from the Johns Hopkins University and an EMBA from the University of Maryland, Smith School of Business. He also holds an M.Sc. from the National University of Singapore and a BS. from Xi’an Jiaotong University. 

Education

• Ph.D., MSE/Whiting School of Engineering, Johns Hopkins University
• EMBA, Robert H. Smith School of Business, University of Maryland, College Park

Research

• X.Lu., … F.Chen*. From Crisis to Innovation in Point-of-Care Testing: Lessons from the COVID-19 Pandemic and Future Directions. TrAC Trends in Analytical Chemistry. 2025 (184): 118-131.  
• F.Chen*, et al, Toward Bridging Gaps in Patient Navigation: A Study on the Adoption of Artificial Intelligence Technologies. Med Adv. 2024; 2(3): 274–83.  
• F.Chen*, et al. Using AI for Patient Navigation during COVID-19 Pandemic: A Case Report. EC Nursing and Healthcare 5.7 (2023): 01-07  
• L.Yuan, … F.Chen*. U.S. Field Hospitals: A Study on Public Health Emergency Response to COVID-19. EC Nursing and Healthcare, 3.2 (2021): 74-86.  

*Corresponding author

Working papers

• Is the World Ready for Novel Medicine “Made in China”? Investigating the Global Strategy for Chinese Biopharmaceutical Innovators. Harvard Business Review (in prep with Professor Toby Egan School of Public Policy, University of Maryland) 

Teaching

Current

• BU.460.730.51 New Product Development
• BU.460.730.52 New Product Development

Impact and engagement

• LINKMedicine.AI (formerly LINKSciences LLC)

In the media

• “Epidemiologic Data Are Critical to Public Health Policymaking,” Phoenix Television, television interview, Jul. 17, 2020.